Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study

[1]  A. Zangrillo,et al.  Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. , 2010, The Journal of thoracic and cardiovascular surgery.

[2]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[3]  F. Mohr,et al.  Postoperative development of aspirin resistance following coronary artery bypass , 2009, European journal of clinical investigation.

[4]  H. Deniz,et al.  Aspirin resistance after CABG. , 2009, The Thoracic and cardiovascular surgeon.

[5]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[6]  M. Kurt,et al.  Detection and duration of aspirin resistance after coronary artery bypass grafting. , 2008, The Journal of thoracic and cardiovascular surgery.

[7]  E. Rota,et al.  Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) , 2008, Thrombosis and Haemostasis.

[8]  M. Gent,et al.  Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  R. Suojaranta-Ylinen,et al.  Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. , 2007, Journal of cardiothoracic and vascular anesthesia.

[10]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[11]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[12]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[13]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[14]  L. Liao,et al.  Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. , 2005, The American journal of cardiology.

[15]  Y. Gruel,et al.  Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodies , 2005, British journal of haematology.

[16]  Robert J Anderson,et al.  Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. , 2004, Journal of the American College of Cardiology.

[17]  C David Naylor,et al.  A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. , 2004, The New England journal of medicine.

[18]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[19]  F. Van de Werf,et al.  A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. , 2004, Journal of the American College of Cardiology.

[20]  W. Karzai,et al.  Aspirin and mortality from coronary bypass surgery. , 2003, The New England journal of medicine.

[21]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[22]  M. Bakhos,et al.  Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. , 2002, The American journal of cardiology.

[23]  S. Doggrell.  Fondaparinux versus enoxaparin for the prevention of venous thromboembolism , 2002, Expert opinion on pharmacotherapy.

[24]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[25]  V. Fuster,et al.  Antithrombotic therapy and venous graft disease. , 1998, Current opinion in cardiology.

[26]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[27]  Mangano Dt.  Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. , 1997, JAMA.

[28]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[29]  S. Yusuf,et al.  Effect of coronary artery bypass graft surgery on survival , 1994, The Lancet.

[30]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[31]  J. Copeland,et al.  Starting Aspirin Therapy After Operation: Effects on Early Graft Patency , 1991, Circulation.

[32]  J. Butterton.  Heparin-Induced Thrombocytopenia Associated with Fondaparinux , 2007 .

[33]  F. Frigoletto,et al.  Focus on Research: Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to Thrombosis , 2007 .

[34]  S. Greene.  Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting , 2006 .

[35]  M. Yılmaz,et al.  Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. , 2005, Thrombosis research.

[36]  G. Agnelli.  Prevention of venous thromboembolism in high risk abdominal surgery , 2003 .

[37]  C. Naylor,et al.  Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. , 1993, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.